Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

PDI Healthcare Hosts Educational Session at AVA 2017 on CHG's Role in CLABSI Prevention

PDI Healthcare
Posted on: 06 Sep 17

PR Newswire

ORANGEBURG, N.Y., Sept. 6, 2017

ORANGEBURG, N.Y., Sept. 6, 2017 /PRNewswire/ -- PDI, a leader in infection prevention products and solutions, today announced it will host an educational session focused on the role of chlorhexidine gluconate (CHG) in central line-associated bloodstream infection (CLABSI) prevention at the 2017 Annual Scientific Meeting of the Association for Vascular Access. The meeting, which will take place at the Phoenix Convention Center in Phoenix, Arizona from Sept. 16-19, will also feature PDI's Prevantics® Device Swab as the subject of a poster presentation highlighting positive impacts and improved CLABSI outcomes at a healthcare facility.

On Sept. 18 from 5:15 to 6:15 p.m., infection prevention expert Joan Hebden, MS, RN, CIC, FAPIC will present a session titled "Chlorhexidine Gluconate: The 'It' Antiseptic?". The session will define CHG's mechanism of action, as well as the mechanism for development of CHG resistance. Attendees will understand the two modes of bacterial pathogenesis into the bloodstream from intravascular device, and review the current CDC recommendations for the use of CHG to prevent CLABSIs.

Additionally, a Virginia-based healthcare facility is presenting a poster that features PDI's Prevantics Device Swab. After experiencing an increase in CLABSI rates, the facility sought an effective way to improve disinfection compliance before every intravenous access. After Prevantics Device Swab was implemented hospital-wide in January 2016, CLABSIs decreased 76% year-over-year, from 17 documented infections in 2015 to four in 2016. The poster concludes that the introduction of the Prevantics Device Swab increases compliance, provides fast and effective disinfection, decreases infections and ultimately improves patient outcomes. The full poster can be viewed online here.

In exhibitor booth #425, PDI also will showcase several marquee products in a simulated hospital room, utilizing a mannequin in a dialysis chair to demonstrate how to:

  • Perform proper hand hygiene with PDI's Sani-Hands® Antimicrobial Wipes
  • Prep skin with PDI's Prevantics® Skin antiseptics
  • Disinfect devices with PDI's Prevantics® Device Swab

About PDI Healthcare
PDI offers a broad range of evidence-based, market-leading Interventional Care, Environment of Care, and Patient Care solutions, all designed to help reduce preventable infections, control healthcare costs, and ultimately help save lives. It's all part of PDI's passion to Be The Difference®, every day. To learn more, visit pdihc.com.  

Media Contact:
Lindsey Schmidt
Kwittken
212-352-6537
lschmidt@kwittken.com

View original content with multimedia:http://www.prnewswire.com/news-releases/pdi-healthcare-hosts-educational-session-at-ava-2017-on-chgs-role-in-clabsi-prevention-300514474.html

SOURCE PDI Healthcare

PR Newswire
www.prnewswire.com

Last updated on: 06/09/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.